Canopy Growth (WEED) is expected to have the highest cannabis growing capacity (HMMJ) compared to Aurora Cannabis (ACB), MedReleaf (MEDFF), and Cronos (CRON). Read more in How Cannabis Companies Are Rushing to Expand Operations.
As of March 22, the consensus analyst mean rating on Canopy Growth was 2.6, which remained unchanged from the previous month. As we can see in the above chart, one analyst continues to have a “strong buy” recommendation and three analysts continue to have a “buy” recommendation on the stock for the next 12-month period.
Also, four analysts have maintained a “hold” recommendation, and one analyst has maintained a “sell” recommendation on the stock.
While the analyst ratings on Canopy Growth remained unchanged month-over-month in March, the consensus mean price target moved higher to 33.6 Canadian dollars from 33.1, while the median price target remained unchanged at 35 Canadian dollars.
Canopy Growth closed at 31.7 Canadian dollars on March 22, which leaves a 6% upside on the stock when compared to the mean price target. However, on comparing with the median price target, we see an upside of almost 10.4% on the stock.
We will continue our discussion with Aurora Cannabis in the next article.